Janet Benesh
About
Janet Benesh is a scholar working on Neurology, Epidemiology and Speech and Hearing.
According to data from OpenAlex, Janet Benesh has authored 28 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Neurology, 13 papers in Epidemiology and 5 papers in Speech and Hearing. Recurrent topics in Janet Benesh's work include Parkinson's Disease Mechanisms and Treatments (21 papers), Neurological disorders and treatments (16 papers) and Restless Legs Syndrome Research (13 papers). Janet Benesh is often cited by papers focused on Parkinson's Disease Mechanisms and Treatments (21 papers), Neurological disorders and treatments (16 papers) and Restless Legs Syndrome Research (13 papers). Janet Benesh collaborates with scholars based in United States, Germany and Australia. Janet Benesh's co-authors include Krai Chatamra, Hubert H. Fernandez, David G. Standaert, Weining Robieson, Alberto J. Espay, Per Odin, Arvydas Vanagunas, Angelo Antonini, Yili Pritchett and Coleen Hall and has published in prestigious journals such as Neurology, The Lancet Neurology and Movement Disorders.
In The Last Decade
Janet Benesh
27 papers receiving 1.2k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Janet Benesh United States | 14 | 1.1k | 313 | 201 | 104 | 97 | 28 | 1.2k | ||
| Víctor Puente Spain | 13 | 471 0.4× | 193 0.6× | 72 0.4× | 27 0.3× | 26 0.3× | 21 | 672 | ||
| Tove Henriksen Denmark | 15 | 909 0.9× | 142 0.5× | 173 0.9× | 21 0.2× | 18 0.2× | 42 | 1.0k | ||
| R. De Notaris Italy | 13 | 468 0.4× | 49 0.2× | 193 1.0× | 24 0.2× | 38 0.4× | 15 | 744 | ||
| Ana Lúcia Zuma de Rosso Brazil | 14 | 372 0.4× | 40 0.1× | 123 0.6× | 54 0.5× | 37 0.4× | 48 | 533 | ||
| Ayaka Numao Japan | 10 | 257 0.2× | 156 0.5× | 39 0.2× | 24 0.2× | 14 0.1× | 23 | 358 | ||
| Muhittin Cenk Akbostancı Türkiye | 12 | 346 0.3× | 66 0.2× | 87 0.4× | 8 0.1× | 26 0.3× | 56 | 479 | ||
| Jason Aldred United States | 12 | 512 0.5× | 66 0.2× | 166 0.8× | 12 0.1× | 11 0.1× | 34 | 633 | ||
| J. Vaamonde Spain | 14 | 703 0.7× | 40 0.1× | 310 1.5× | 7 0.1× | 62 0.6× | 45 | 898 | ||
| A Ingela M Nilsson Remahl Sweden | 9 | 366 0.3× | 81 0.3× | 76 0.4× | 14 0.1× | 18 0.2× | 12 | 465 | ||
| Onanong Jitkritsadakul Thailand | 15 | 457 0.4× | 75 0.2× | 127 0.6× | 14 0.1× | 21 0.2× | 28 | 558 |
Countries citing papers authored by Janet Benesh
Since
Specialization
Citations
This map shows the geographic impact of Janet Benesh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Janet Benesh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Janet Benesh more than expected).
Fields of papers citing papers by Janet Benesh
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Janet Benesh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Janet Benesh. The network helps show where Janet Benesh may publish in the future.
Co-authorship network of co-authors of Janet Benesh
This figure shows the co-authorship network connecting the top 25 collaborators of Janet Benesh. A scholar is included among the top collaborators of Janet Benesh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Janet Benesh. Janet Benesh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Facheris, Maurizio, et al.. (2020). Safety and Tolerability in Parkinson’s Disease Patients Treated with a Continuous Subcutaneous Infusion of ABBV-951: Design of a 52-Week Phase 3 Study (4233). Neurology. 94(15_supplement).
2.
Boyd, James T., Cindy Zadikoff, Janet Benesh, et al.. (2019). A post hoc comparison of levodopa-carbidopa intestinal gel daytime monotherapy vs polytherapy safety and efficacy in patients with advanced Parkinson's disease: Results from 6 phase 3/3b open-label studies. Clinical Parkinsonism & Related Disorders. 2. 25–34.
3.
Fernandez, Hubert H., James T. Boyd, Victor S.C. Fung, et al.. (2018). Long‐term safety and efficacy of levodopa‐carbidopa intestinal gel in advanced Parkinson's disease. Movement Disorders. 33(6). 928–936.
4.
Boyd, James T., Cindy Zadikoff, Janet Benesh, et al.. (2017). Safety and efficacy of levodopa-carbidopa monotherapy in patients with advanced parkinson’s disease. Journal of the Neurological Sciences. 381. 182–183.
5.
Murata, Miho, Masahito Mihara, Kazuko Hasegawa, et al.. (2016). Efficacy and safety of levodopa–carbidopa intestinal gel from a study in Japanese, Taiwanese, and Korean advanced Parkinson’s disease patients. npj Parkinson s Disease. 2(1). 16020–16020.
6.
Epstein, Michael, David A. Johnson, Robert H. Hawes, et al.. (2016). Long-Term PEG-J Tube Safety in Patients With Advanced Parkinson's Disease. Clinical and Translational Gastroenterology. 7(3). e159–e159.
7.
Fernandez, Hubert H., Weining Robieson, Krai Chatamra, et al.. (2016). Effect of levodopa-carbidopa intestinal gel on resting tremors in patients with advanced Parkinson’s disease. npj Parkinson s Disease. 2(1). 16015–16015.
8.
Antonini, Angelo, Victor S.C. Fung, James T. Boyd, et al.. (2016). E ffect of levodopa‐carbidopa intestinal gel on dyskinesia in advanced P arkinson's disease patients. Movement Disorders. 31(4). 530–537.
9.
Slevin, John T., Hubert H. Fernandez, Cindy Zadikoff, et al.. (2015). Long-Term Safety and Maintenance of Efficacy of Levodopa-Carbidopa Intestinal Gel: An Open-Label Extension of the Double-Blind Pivotal Study in Advanced Parkinson's Disease Patients. Journal of Parkinson s Disease. 5(1). 165–174.
10.
Dubow, Jordan, Krai Chatamra, Susan Eaton, Coleen Hall, & Janet Benesh. (2015). Interim Results of a Phase 3b Study Assessing the Safety and Efficacy of Levodopa-Carbidopa Intestinal Gel On Non-Motor Symptoms in Subjects with Advanced Parkinson’s Disease (P6.041). Neurology. 84(14_supplement).
11.
Lew, Mark, John T. Slevin, Rejko Krüger, et al.. (2015). Initiation and dose optimization for levodopa-carbidopa intestinal gel: Insights from phase 3 clinical trials. Parkinsonism & Related Disorders. 21(7). 742–748.
12.
Othman, Ahmed A., Krai Chatamra, Mohamed‐Eslam F. Mohamed, et al.. (2015). Jejunal Infusion of Levodopa–Carbidopa Intestinal Gel Versus Oral Administration of Levodopa–Carbidopa Tablets in Japanese Subjects with Advanced Parkinson’s Disease: Pharmacokinetics and Pilot Efficacy and Safety. Clinical Pharmacokinetics. 54(9). 975–984.
13.
Antonini, Angelo, Victor S.C. Fung, James T. Boyd, et al.. (2014). Changes In Troublesome Dyskinesia And Its Relationship With Dose In Advanced Parkinson’s Disease Patients Treated With Levodopa-Carbidopa Intestinal Gel Infusion (P7.071). Neurology. 82(10_supplement).
14.
Epstein, Michael, David H. Johnson, Robert H. Hawes, et al.. (2014). Gastrointestinal Safety of the Levodopa-Carbidopa Intestinal Gel Delivery System in Treating Advanced Parkinson’s Patients (P7.085). Neurology. 82(10_supplement).
15.
Fernandez, Hubert H., David G. Standaert, Robert A. Hauser, et al.. (2014). Levodopa‐carbidopa intestinal gel in advanced Parkinson's disease: Final 12‐month, open‐label results. Movement Disorders. 30(4). 500–509.
16.
Fernandez, Hubert H., Arvydas Vanagunas, Per Odin, et al.. (2013). Levodopa–carbidopa intestinal gel in advanced Parkinson's disease open-label study: Interim results. Parkinsonism & Related Disorders. 19(3). 339–345.
17.
Olanow, C. Warren, Karl Kieburtz, Per Odin, et al.. (2013). Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study. The Lancet Neurology. 13(2). 141–149.
18.
Rogol, Alan D., Ronald S. Swerdloff, Edward O. Reiter, et al.. (2013). A Multicenter, Open-Label, Observational Study of Testosterone Gel (1%) in the Treatment of Adolescent Boys With Klinefelter Syndrome or Anorchia. Journal of Adolescent Health. 54(1). 20–25.
19.
Espay, Alberto J., Per Odin, Hubert H. Fernandez, et al.. (2013). A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: safety and motor-symptom endpoints. Journal of the Neurological Sciences. 333. e127–e127.
20.
Standaert, David G., Hubert H. Fernandez, Per Odin, et al.. (2013). A long-term, open-label study of levodopa–/INS;carbidopa intestinal gel in advanced Parkinson's disease patients: Functional and health-related quality-of-life endpoints. Journal of the Neurological Sciences. 333. e123–e124.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Víctor Puente Breakdown of academic impact, for papers by Tove Henriksen Breakdown of academic impact, for papers by R. De Notaris Breakdown of academic impact, for papers by Ana Lúcia Zuma de Rosso Breakdown of academic impact, for papers by Ayaka Numao Breakdown of academic impact, for papers by Muhittin Cenk Akbostancı Breakdown of academic impact, for papers by Jason Aldred Breakdown of academic impact, for papers by J. Vaamonde Breakdown of academic impact, for papers by A Ingela M Nilsson Remahl Breakdown of academic impact, for papers by Onanong Jitkritsadakul